EFFECTIVENESS OF LOW-DOSE HEPARIN IN PREVENTION OF MYOCARDIAL REINFARCTION

G. G. Neri Serneri, G. F. Gensini, M. Carnovali, F. Rovelli, S. Pirelli, A. Fortini

Research output: Contribution to journalArticle

81 Citations (Scopus)

Abstract

728 patients aged 50-75 years who had had Q-wave myocardial infarction 6-18 months previously were enrolled in a randomised, multicentre trial of low-dose heparin in prevention of reinfarction. The control group (365 patients) received their study centres' usual therapy; the heparin group (363 patients) also received subcutaneous calcium heparin (12 500 IU daily). Mean (SD) follow-up was 708 (265) days in the heparin group and 687 (251) in the control group. The reinfarction rate was 63% lower in the heparin than in the control group (4/303, 1·32% υ 13/365, 3·56%). The difference in cumulative reinfarction rate between the groups was significant by both drug-efficacy (χ2=3·99, p2=3·84, p=0·05). Heparin treatment reduced the cumulative general mortality rates by 48% on drug-efficacy analysis (χ2=3·88, p2=2·05, not significant). Cardiovascular mortality was also reduced (33%) but not significantly. However, fatal events attributable to thromboembolism (fatal reinfarction, stroke, pulmonary embolism) were significantly less frequent in the heparin than in the control group (1 υ 7, p

Original languageEnglish
Pages (from-to)937-942
Number of pages6
JournalLancet
Volume329
Issue number8539
DOIs
Publication statusPublished - Apr 25 1987

Fingerprint

Heparin
Control Groups
Mortality
Thromboembolism
Pulmonary Embolism
Pharmaceutical Preparations
Multicenter Studies
Stroke
Myocardial Infarction
Therapeutics

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Neri Serneri, G. G., Gensini, G. F., Carnovali, M., Rovelli, F., Pirelli, S., & Fortini, A. (1987). EFFECTIVENESS OF LOW-DOSE HEPARIN IN PREVENTION OF MYOCARDIAL REINFARCTION. Lancet, 329(8539), 937-942. https://doi.org/10.1016/S0140-6736(87)90291-1

EFFECTIVENESS OF LOW-DOSE HEPARIN IN PREVENTION OF MYOCARDIAL REINFARCTION. / Neri Serneri, G. G.; Gensini, G. F.; Carnovali, M.; Rovelli, F.; Pirelli, S.; Fortini, A.

In: Lancet, Vol. 329, No. 8539, 25.04.1987, p. 937-942.

Research output: Contribution to journalArticle

Neri Serneri, GG, Gensini, GF, Carnovali, M, Rovelli, F, Pirelli, S & Fortini, A 1987, 'EFFECTIVENESS OF LOW-DOSE HEPARIN IN PREVENTION OF MYOCARDIAL REINFARCTION', Lancet, vol. 329, no. 8539, pp. 937-942. https://doi.org/10.1016/S0140-6736(87)90291-1
Neri Serneri GG, Gensini GF, Carnovali M, Rovelli F, Pirelli S, Fortini A. EFFECTIVENESS OF LOW-DOSE HEPARIN IN PREVENTION OF MYOCARDIAL REINFARCTION. Lancet. 1987 Apr 25;329(8539):937-942. https://doi.org/10.1016/S0140-6736(87)90291-1
Neri Serneri, G. G. ; Gensini, G. F. ; Carnovali, M. ; Rovelli, F. ; Pirelli, S. ; Fortini, A. / EFFECTIVENESS OF LOW-DOSE HEPARIN IN PREVENTION OF MYOCARDIAL REINFARCTION. In: Lancet. 1987 ; Vol. 329, No. 8539. pp. 937-942.
@article{a3cdfc8326a04113a7b859730422dbd3,
title = "EFFECTIVENESS OF LOW-DOSE HEPARIN IN PREVENTION OF MYOCARDIAL REINFARCTION",
abstract = "728 patients aged 50-75 years who had had Q-wave myocardial infarction 6-18 months previously were enrolled in a randomised, multicentre trial of low-dose heparin in prevention of reinfarction. The control group (365 patients) received their study centres' usual therapy; the heparin group (363 patients) also received subcutaneous calcium heparin (12 500 IU daily). Mean (SD) follow-up was 708 (265) days in the heparin group and 687 (251) in the control group. The reinfarction rate was 63{\%} lower in the heparin than in the control group (4/303, 1·32{\%} υ 13/365, 3·56{\%}). The difference in cumulative reinfarction rate between the groups was significant by both drug-efficacy (χ2=3·99, p2=3·84, p=0·05). Heparin treatment reduced the cumulative general mortality rates by 48{\%} on drug-efficacy analysis (χ2=3·88, p2=2·05, not significant). Cardiovascular mortality was also reduced (33{\%}) but not significantly. However, fatal events attributable to thromboembolism (fatal reinfarction, stroke, pulmonary embolism) were significantly less frequent in the heparin than in the control group (1 υ 7, p",
author = "{Neri Serneri}, {G. G.} and Gensini, {G. F.} and M. Carnovali and F. Rovelli and S. Pirelli and A. Fortini",
year = "1987",
month = "4",
day = "25",
doi = "10.1016/S0140-6736(87)90291-1",
language = "English",
volume = "329",
pages = "937--942",
journal = "The Lancet",
issn = "0140-6736",
publisher = "Lancet Publishing Group",
number = "8539",

}

TY - JOUR

T1 - EFFECTIVENESS OF LOW-DOSE HEPARIN IN PREVENTION OF MYOCARDIAL REINFARCTION

AU - Neri Serneri, G. G.

AU - Gensini, G. F.

AU - Carnovali, M.

AU - Rovelli, F.

AU - Pirelli, S.

AU - Fortini, A.

PY - 1987/4/25

Y1 - 1987/4/25

N2 - 728 patients aged 50-75 years who had had Q-wave myocardial infarction 6-18 months previously were enrolled in a randomised, multicentre trial of low-dose heparin in prevention of reinfarction. The control group (365 patients) received their study centres' usual therapy; the heparin group (363 patients) also received subcutaneous calcium heparin (12 500 IU daily). Mean (SD) follow-up was 708 (265) days in the heparin group and 687 (251) in the control group. The reinfarction rate was 63% lower in the heparin than in the control group (4/303, 1·32% υ 13/365, 3·56%). The difference in cumulative reinfarction rate between the groups was significant by both drug-efficacy (χ2=3·99, p2=3·84, p=0·05). Heparin treatment reduced the cumulative general mortality rates by 48% on drug-efficacy analysis (χ2=3·88, p2=2·05, not significant). Cardiovascular mortality was also reduced (33%) but not significantly. However, fatal events attributable to thromboembolism (fatal reinfarction, stroke, pulmonary embolism) were significantly less frequent in the heparin than in the control group (1 υ 7, p

AB - 728 patients aged 50-75 years who had had Q-wave myocardial infarction 6-18 months previously were enrolled in a randomised, multicentre trial of low-dose heparin in prevention of reinfarction. The control group (365 patients) received their study centres' usual therapy; the heparin group (363 patients) also received subcutaneous calcium heparin (12 500 IU daily). Mean (SD) follow-up was 708 (265) days in the heparin group and 687 (251) in the control group. The reinfarction rate was 63% lower in the heparin than in the control group (4/303, 1·32% υ 13/365, 3·56%). The difference in cumulative reinfarction rate between the groups was significant by both drug-efficacy (χ2=3·99, p2=3·84, p=0·05). Heparin treatment reduced the cumulative general mortality rates by 48% on drug-efficacy analysis (χ2=3·88, p2=2·05, not significant). Cardiovascular mortality was also reduced (33%) but not significantly. However, fatal events attributable to thromboembolism (fatal reinfarction, stroke, pulmonary embolism) were significantly less frequent in the heparin than in the control group (1 υ 7, p

UR - http://www.scopus.com/inward/record.url?scp=0023092605&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023092605&partnerID=8YFLogxK

U2 - 10.1016/S0140-6736(87)90291-1

DO - 10.1016/S0140-6736(87)90291-1

M3 - Article

C2 - 2882339

AN - SCOPUS:0023092605

VL - 329

SP - 937

EP - 942

JO - The Lancet

JF - The Lancet

SN - 0140-6736

IS - 8539

ER -